Answers are grounded in this paper and cite their sources.
The antihypertensive and heart-failure drug ranolazine, it is not very soluble in water and does not absorb well in the mouth, thus it is not very useful as a medicine.To boost its oral bioavailability, our study created Ranolazine-loaded solid lipid nanoparticles (Ranolazine-SLNs).Using design of experiments principles, we synthesized ranolazine -SLNs by a hot homogenization and ultra-sonication process.The formulation variables of lipid X1 (glyceryl monostearate), surfactant X2 (Tween 80), and sonication duration X3 were optimized using a central composite design.All of the solid lipid nanoparticle formulations developed had nanometre-sized, spherical particles with high absolute values of zeta potential, indicating excellent long-term stability.The Ranolazine-SLNs studied in vitro showed a regulated release profile lasting for at least 24 h.Drug release from the solid lipid nanoparticles was revealed to be much greater than drug suspension via studies using dialysis sacs, stomachs, and intestinal tissues from rats.The relative bioavailability of Ranolazine-SLNs was found to be almost 2.3 times that of the commercially available formulation, with a max of 3.9463.95ng/ml, an AUC of 84.7062.31ng/ml, and a higher AUC.Based on these findings, Ranolazine-SLNs are a promising new approach to treating hypertension due to their improved bioavailability and positive therapeutic effects.Therefore, these solid lipid nanoparticles may provide a promising alternative to the standard oral formulation for the management of hypertension.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: